Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase I Clinical Trial of Autologous T Cells Transduced With NY-ESO-1 Antigen-specific High-affinity T Cell Receptors in NY-ESO-1-positive Patients With Advanced Solid Tumors

NCT06942143 is registered in ClinicalTrials.gov with Guangzhou FineImmune Biotechnology Co., LTD. as lead sponsor.

NCT NCT06942143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06942143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase I Clinical Trial of Autologous T Cells Transduced With NY-ESO-1 Antigen-specific High-affinity T Cell Receptors in NY-ESO-1-positive Patients With Advanced Solid Tumors
Lead sponsor
Guangzhou FineImmune Biotechnology Co., LTD.
Phase
Phase 1
Overall status
Recruiting
Start date
May 22, 2025
Completion date
June 25, 2027
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancers, melanoma, sarcoma